Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Trial Profile

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs ABBV-155 (Primary) ; Docetaxel; Paclitaxel
  • Indications Breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Feb 2019 Planned End Date changed from 30 Sep 2020 to 29 Apr 2021.
    • 08 Feb 2019 Planned primary completion date changed from 30 Sep 2020 to 29 Apr 2021.
    • 08 Feb 2019 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top